BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $57.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

JPMorgan Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)November 5, 2024 2:56 PM Stifel Defending Beam Therapeutics Inc (BEAM): 'Reactions To Initial BEAM-101 Update Strikes Us As Overreaction'November 5, 2024 11:47 AM Form 8-K Beam Therapeutics Inc. For: Nov 05November 5, 2024 8:31 AM Form 8-K Beam Therapeutics Inc. For: Nov 05November 5, 2024 7:05 AM Beam, Inc. (BEAM) Tops Q3 EPS by 1cNovember 5, 2024 6:39 AM Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsNovember 5, 2024 6:30 AM